Low or undetectable TPO receptor expression in malignant tissue and cell lines derived from breast, lung, and ovarian tumors

por Erickson-Miller, Connie L, Pillarisetti, Kodandaram, Kirchner, Jennifer, Figueroa, David J, Ottesen, Lone, Martin, Anne-Marie, Liu, Yuan, Kamel, Yasser Mostafa, Messam, Conrad
Publicado 2012

Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors

por Någård, Mats, Ah-See, Mei-Lin, Strauss, James, Wise-Draper, Trisha, Safran, Howard P., Nadeau, Laura, Edenfield, William J., Lewis, Lionel D., Ottesen, Lone H., Li, Yan, Mugundu, Ganesh M.
Publicado 2023

Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors

por Någård, Mats, Ah-See, Mei-Lin, So, Karen, Vermunt, Marit, Thistlethwaite, Fiona, Labots, Mariette, Roxburgh, Patricia, Ravaud, Alain, Campone, Mario, Valkenburg-van Iersel, Liselot, Ottesen, Lone, Li, Yan, Mugundu, Ganesh
Publicado 2020

Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial

por Choueiri, Toni K., Heng, Daniel Y. C., Lee, Jae Lyun, Cancel, Mathilde, Verheijen, Remy B., Mellemgaard, Anders, Ottesen, Lone H., Frigault, Melanie M., L’Hernault, Anne, Szijgyarto, Zsolt, Signoretti, Sabina, Albiges, Laurence
Publicado 2020

Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study

por Någård, Mats, Ah-See, Mei-Lin, Strauss, James, Wise-Draper, Trisha, Safran, Howard P., Nadeau, Laura, Edenfield, William J., Lewis, Lionel D., Rekić, Dinko, Dota, Corina, Ottesen, Lone H., Li, Yan, Mugundu, Ganesh M.
Publicado 2023